SERA PROGNOSTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
SERA PROGNOSTICS, INC. (SERA) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $454.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $231.00K, a 80.54% decline year-over-year.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $1.19M, a 230.64% increase year-over-year.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $359.00K.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$2.68M, a 152.00% decline year-over-year.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$99.00K, a 160.74% decline from fiscal 2024.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $163.00K.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$26.00M.
- SERA PROGNOSTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$29.05M, a 164.00% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $454.00K 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $231.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$99.00K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $38.00K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $973.00K 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $1.19M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $163.00K 10-K · filed 2026-03-18 | |||
| 2024-09-30 | -$1.20M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $784.00K 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $359.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$26.00M 10-K · filed 2025-03-19 | |||
| 2023-09-30 | -$20.22M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $2.41M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$2.68M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$29.05M 10-K · filed 2024-03-20 | |||
| 2022-09-30 | -$20.12M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$5.04M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $5.15M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $45.40M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $68.95M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $77.32M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $46.48M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$7.86M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | -$2.71M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $2.24M 10-Q · filed 2021-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |